(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid | 257904-60-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
• CAS: 257904-60-2
• 化学式: C₂₃H₄₇N₁₃O₅
• 分子量: 585.7
• InChiKey: FZUNZKQWLWOQFH-VGWMRTNUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -8
• 重原子数：
  41
• 可旋转键数：
  20
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  344
• 氢给体数：
  11
• 氢受体数：
  9

文献信息

• Use of convertase inhibitors in the treatment of fibrosis and scarring
  申请人：Ferguson James Mark William

  公开号：US20060052309A1

  公开（公告）日：2006-03-09

  The present invention relates to use of convertase inhibitors for the reduction of scarring during the healing of wounds and also for reducing fibrosis in the treatment of fibrotic conditions.

  本发明涉及转化酶抑制剂在伤口愈合过程中用于减少瘢痕，以及在治疗纤维化病症过程中用于减少纤维化。
• USE OF CONVERTASE INHIBITORS IN THE TREATMENT OF FIBROSIS AND SCARRING
  申请人：Renovo Limited

  公开号：EP1556080A1

  公开（公告）日：2005-07-27
• Therapeutic protease compositions
  申请人：Parmely Michael J.

  公开号：US20080081035A1

  公开（公告）日：2008-04-03

  A method of treating an inflammatory condition involving TNF-α in a mammal by administering to a patient a composition with an effective amount of an isolated alkaline protease in an amount effective to inactive TNF-α. The invention also involves compositions, including pharmaceutical compositions containing an isolated alkaline protease in an amount effective to inactive TNF-α especially those from Aspergillus oryzae.
• THERAPEUTIC ALKALINE PROTEASE COMPOSITIONS AND USE IN FACILITATING THE TRANSPORT OF AGENTS ACROSS THE GASTROINTESTINAL MUCOSAL LINING
  申请人：Parmely Michael J.

  公开号：US20090068174A1

  公开（公告）日：2009-03-12

  A method of treating an inflammatory condition involving TNF-α in a mammal by administering to a patient a composition with an effective amount of an isolated alkaline protease in an amount effective to inactive TNF-α. The invention also involves compositions, including pharmaceutical compositions containing an isolated alkaline protease in an amount effective to inactive TNF-α especially those from Aspergillus oryzae and/or serve as a transepithial carrier.
• USE OF FURIN CONVERTASE INHIBITORS IN THE TREATMENT OF FIBROSIS AND SCARRING
  申请人：FERGUSON Mark William James

  公开号：US20110059896A1

  公开（公告）日：2011-03-10

  The present invention relates to use of convertase inhibitors for the reduction of scarring during the healing of wounds and also for reducing fibrosis in the treatment of fibrotic conditions.